Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386579 | 0.83 | KMT2A (0.84) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL7564728 | 0.83 | KMT2A (0.84) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL8200020 | 0.83 | KMT2A (0.84) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL1046239 | 0.82 | USP2 (0.76) | POLBLMNASMN1; SMN2USP2TSHR | |
| SCHEMBL160108 | 0.81 | ATM (0.69) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL16503462 | 0.81 | ATM (0.69) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL8728928 | 0.81 | ATM (0.69) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL1156725 | 0.81 | ATM (0.69) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL424172 | 0.81 | PKM (0.71) | ATMPOLBLMNASMN1; SMN2USP2 | |
| SCHEMBL2964267 | 0.81 | ATM (0.69) | ATMPOLBLMNASMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| EP-2342178-B1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2016-09-28 | — | — | EP | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| WO-2010025856-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-11 | — | — | WO | disclosed |
| EP-1322602-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6399824-B1 | FOR THERAPY AND PROPHYLAXIS OF ARRHYTHMIAS, CARDIAC INFRACTION, ISCHEMIC CONDITIONS, ANGINA PECTORIS, SHOCK, FOR PRESERVING AND STORING A TRANSPLANT FOR SURGICAL MEASURE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-04 | — | — | US | disclosed |
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2002-05-16 | — | — | US | disclosed |
| WO-2002024637-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | GANC, GMPS, GCDH | ATM 2367/4885POLB 2328/4885LMNA 431/4885 |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, PKD1 | ATM 1187/4885POLB 2810/4885LMNA 2738/4885 |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, FANCI | ATM 1120/4885POLB 2958/4885LMNA 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.